Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

NCT07095517 · Recruiting

Last updated 2026-05-28

This trial tests whether a medication can help prevent early-onset colorectal tumors in people at higher risk, by measuring changes in a specific molecule in their urine.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) prevention study

Participants 20 people Planned (estimated).

Who can join Ages 18–50 · all sexes

Timeline Started 2026-02 · est. completion 2028-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07095517 ↗

Description as written by the study sponsor.

This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.

Treatments tested

Tirzepatide also known as Zepbound Drug

Study drug injected subcutaneously once a week

Main thing measured	Change in Urinary PGE-M
Sponsor	Massachusetts General Hospital
Conditions studied	Colorectal Cancer Prevention, Colorectal Adenoma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07095517 ↗